- Home >
- Clinicals Trials >
- SALVOVAR
Cancer de l'ovaire
SALVOVAR
A pragmatic randomized phase III trial to assess the utility of adjusting;chemotherapy dose & dosing schedule with the SALVage weekly dose-dense;regimen in patients with poor prognostic OVARian cancers based on the tumor;unfavorable primary chemosensitivity and incomplete debulking surgery.
- Open at Paris since : 06/11/2024
- Open at Saint-Cloud since : 01/05/2024
- Target : Adult
- Phase : Phase III
Trial description
To demonstrate the superiority in terms of efficacy of a densification of the;chemotherapy with the salvage weekly dose-dense carboplatin-paclitaxel;regimen compared to the continuation of the standard 3-weekly;carboplatin-paclitaxel, in ovarian cancer patients found to have a poor;prognostic disease (characterized by a poor chemosensitivity, with an;unfavorable KELIMTM score < 1.0, and a disease not amenable to complete;interval debulking surgery) after 3 to 4 cycles of standard neo-adjuvant;chemotherapy.
Url of the trialMain investigator
